Continuous Manufacturing On Horizon As Competitive Edge In OTC Space
This article was originally published in The Pink Sheet Daily
While OTC firms’ slimmer profit margins make equipment changes or other capital investments more difficult than for Rx firms, continuous manufacturing will be worth the investment, says CDER Director Janet Woodcock. “We’re going to see a lot of these out there,” she says.
You may also be interested in...
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.
Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.
Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.